Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 14 for:    iab22M2C OR crefmirlimab

CD8+ PET Companion Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05279027
Recruitment Status : Enrolling by invitation
First Posted : March 15, 2022
Last Update Posted : June 1, 2022
Sponsor:
Collaborator:
ImaginAb, Inc.
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
Study of 89Zr-Df-IAB22M2C PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable disease based on RECIST 1.1 are potentially eligible. Associations with progression-free survival (PFS) and overall survival (OS) will be tested.

Condition or disease Intervention/treatment Phase
Melanoma (Skin) Drug: 89Zr-Df-IAB22M2C PET/CT Early Phase 1

Detailed Description:

This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma. This study is a companion imaging study to the "LIMIT Melanoma Trial". Patients with melanoma who are candidates for the LIMIT Melanoma treatment trial and are at least 18 years of age may be eligible. All participants will be receiving care at the clinical practices of the University of Pennsylvania. Patients will be approached about study participation regardless of race or ethnic background. We anticipate enrolling up to 20 evaluable participants with melanoma who meet eligibility requirements for this study. An evaluable patient has completed Baseline and at the post-Treatment 89Zr-Df-IAB22M2C PET/CT scans. Accrual is estimated to occur over approximately 3 years.

After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a Baseline 89Zr-Df-IAB22M2C PET/CT scan prior to starting immunotherapy + HCQ therapy. For the Baseline study, subjects will be injected with 89Zr-Df-IAB22M2C up to 8 days prior to starting therapy (Day -8 to 0), and will undergo PET/CT imaging 24 ± 4 hours post injection, and prior to therapy administration. Subjects will then undergo a Post-Treatment 89Zr-Df-IAB22M2C PET/CT scan at day 12 (± 2 days) post therapy, which will require administration of 89Zr-Df-IAB22M2C on the day prior to the scan. 89Zr-Df-IAB22M2C PET/CT scans will be acquired with an interval of ≥ 12 days between scans, to ensure that the signal from the previous injection of 89Zr-Df-IAB22M2C has decayed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: 89Zr-Df-IAB22M2C (Anti-CD8 Minibody) PET/CT Imaging as a Measure of Response in Patients With Advanced Melanoma on Immunotherapy Plus Hydroxychloroquine.
Actual Study Start Date : March 8, 2022
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : February 28, 2025

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: PET imaging
This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.
Drug: 89Zr-Df-IAB22M2C PET/CT
89Zr-Df-IAB22M2C PET/CT scans pre and post therapy initiation




Primary Outcome Measures :
  1. 89Zr-Df-IAB22M2C uptake [ Time Frame: 21 days ]
    89Zr-Df-IAB22M2C measured uptake *(by standard uptake value) on Baseline and post-Treatment PET/CT scans in tumor lesions and lymphoid organs.

  2. Change in uptake post therapy [ Time Frame: 21 days ]
    Measurement of change in 89Zr-Df-IAB22M2C uptake between Baseline and post-Treatment PET/CT scans in tumor lesions and lymphoid organs.


Secondary Outcome Measures :
  1. Post therapy outcomes [ Time Frame: until the end of the study, usually about 3 years ]
    Association between change in tumor 89Zr-Df-IAB22M2C uptake and objective response, progression free survival, and overall survival.

  2. CD8+ TIL density in tumor [ Time Frame: 2 months ]
    Association between tumor 89Zr-Df-IAB22M2C uptake and CD8+ TIL density in biopsied tumors.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients, at least 18 years of age
  2. History of histologically confirmed melanoma as assessed per medical record review.
  3. At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.
  4. Potentially eligible to participate in the LIMIT Melanoma Trial.
  5. Patients must have adequate baseline organ function as determined per LIMIT Melanoma Trial (IRB 835033) (these tests will be completed as part of LIMIT trial screening and will not be repeated for the imaging companion study)

    Adequate organ function: per LIMIT Melanoma Trial (IRB 35033)

    System Laboratory Values Hematologic Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L Hemoglobin ≥ 9 g/dL Platelet Count ≥ 100 x 109/L PT/INRa and PTT ≤ 1.3 x ULN Hepatic Total Bilirubinb ≤ 1.5 x ULN AST and ALT ≤ 2.5 x ULN Renal Serum Creatinine ≤ 1.5 mg/dL Abbreviations: ALT = alanine transaminase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; INR = international normalized ratio; LLN = lower limit of normal; PT = prothrombin time; PTT = partial thromboplastin time; ULN = upper limit of normal.

    a Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to enrollment.

    b Subjects with known Gilbert's syndrome must have a total bilirubin < 3.0 x ULN).

    c If serum creatinine is > 1.5 mg/dL, calculate creatinine clearance using standard Cockcroft-Gault formula. Creatinine clearance must be ≥ 50 mL/min to be eligible.

  6. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

  1. Females who report they are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test prior to infusion of the study radiotracer to confirm they are not pregnant.
  2. Patients who have any splenic disorders, or had splenectomy, that in the opinion of an investigator could compromise protocol objectives.
  3. Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
  4. Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
  5. Ineligible for the LIMIT Melanoma Trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05279027


Locations
Layout table for location information
United States, Pennsylvania
Perleman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
ImaginAb, Inc.
Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT05279027    
Other Study ID Numbers: 844867
First Posted: March 15, 2022    Key Record Dates
Last Update Posted: June 1, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Abramson Cancer Center of the University of Pennsylvania:
Positron Emission Tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas